Delcath Systems, Inc. (DCTH)

Healthcare
|
Long
  • A unique FDA-approved system of liver-directed treatment for adult patients with uveal melanoma: known as the Hepzato Kit in the U.S. and Chemosat in Europe, the Delcath System’s system uses Percutaneous Hepatic Perfusion (PHP)—a minimally invasive technique that delivers chemotherapy directly to the liver. This targeted approach allows for higher drug concentrations while minimizing systemic side effects compared to conventional chemotherapy.
  • Significant total addressable market and near-term profitability: the PHP therapy is projected to treat 240 patients annually in the US, representing a significant revenue opportunity, with profitability anticipated by Q4 2024. 
  • Investment thesis: the treatment’s slower uptake compared to pill-based therapies may likely result in compelling entry points through 2024 and 2025.

General Partner

Quantinnova S.à r.l.
51 rue du Soleil,
L-2544, Luxembourg
AIFM: A3587 I VAT: LU34495782

Fund Administrator

CreaPartners S.à r.l.
2C Parc d'Activités,
L-8308, Luxembourg

Contact Information

Past performance of Quantamental Global Equity (the “Fund”) is not indicative of future results. No representations or warranties of any kind are made or intended, and none should be inferred, with respect to the economic return or the tax consequences from a potential investment in the Funds. Each investor should consult their own counsel and accountant for advice concerning the various legal, tax and economic matters concerning their investment. The information provided herein does not constitute an offer to sell an interest in the Fund. Such offer can only be made to qualified investors pursuant to the Funds’ Issue Terms and the Subscription Documents relating thereto and the Limited Partnership Agreement, as applicable, which set forth the complete terms of the offer.

No representation or warranty (express or implied) is made or can be given with respect to the accuracy or completeness of the information found within this website. Certain information constitutes “forward-looking statements” about potential future results. Those results may not be achieved, due to implementation lag, other timing factors, portfolio management decision-making, economic or market conditions or other unanticipated factors. Nothing contained herein shall be relied upon as a promise or representation whether as to past or future performance or otherwise.

Full Disclaimer
Copyright © 2026,  Quantinnova S.à r.l. - All rights Reserved.